Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Cancer Research

• Publication date

  2018-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1158/0008-5472.CAN-17-3932PMID 29735549PMCID PMC5985963
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications

  2018influential reference
• A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients

  2017cited by this paper
• Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia.

  2017cited by this paper
• Pharmacokinetics and Drug Interactions Determine Optimum Combination Strategies in Computational Models of Cancer Evolution.

  2017cited by this paper
• Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma.

  2017cited by this paper
• Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.

  2017cited by this paper
• A quantitative FastFUCCI assay defines cell cycle dynamics at a single-cell level

  2017influential reference
• Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer

  2016cited by this paper
• Two is better than one; toward a rational design of combinatorial therapy.

  2016cited by this paper
• Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors

  2016cited by this paper
• Pancreatic cancer

  2016cited by this paper
• COSMIC: somatic cancer genetics at high-resolution

  2016cited by this paper
• Profiling DNA damage response following mitotic perturbations

  2016cited by this paper
• Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.

  2016cited by this paper
• Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress.

  2016cited by this paper
• Schedule-dependent interaction between anticancer treatments

  2016cited by this paper
• Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.

  2015cited by this paper
• Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase.

  2015cited by this paper
• CHK1 Inhibition Synergizes with Gemcitabine Initially by Destabilizing the DNA Replication Apparatus.

  2015influential reference
• Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation

  2015cited by this paper
• Replication stress activates DNA repair synthesis in mitosis

  2015cited by this paper
• Will targeting Chk1 have a role in the future of cancer therapy?

  2015cited by this paper
• Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors.

  2015cited by this paper
• Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example

  2015influential reference
• Application of Evolutionary Principles to Cancer Therapy.

  2015cited by this paper
• Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma

  2015influential reference
• Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair12

  2015cited by this paper
• Combined Inhibition of Wee1 and PARP1/2 for Radiosensitization in Pancreatic Cancer

  2014cited by this paper
• ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.

  2014cited by this paper
• Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

  2014influential reference
• Evolutionary dynamics of cancer in response to targeted combination therapy

  2013cited by this paper
• Pancreatic cancer.

  2013cited by this paper
• Sensitization of Pancreatic Cancer to Chemoradiation by the Chk1 Inhibitor MK8776

  2013cited by this paper
• Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma.

  2013influential reference
• Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo

  2013cited by this paper
• From Bench to Bedside: Lessons Learned in Translating Preclinical Studies in Cancer Drug Development

  2013cited by this paper
• ATR prohibits replication catastrophe by preventing global exhaustion of RPA.

  2013cited by this paper
• Cyclin-Dependent Kinase Suppression by WEE1 Kinase Protects the Genome through Control of Replication Initiation and Nucleotide Consumption

  2012cited by this paper
• Targeting the S and G2 checkpoint to treat cancer.

  2012cited by this paper
• Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1.

  2012cited by this paper
• Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks.

  2012cited by this paper
• WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe

  2011cited by this paper
• MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts

  2011cited by this paper
• Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening

  2011cited by this paper
• Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse

  2010cited by this paper
• The ATR barrier to replication-born DNA damage.

  2010cited by this paper
• Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

  2009cited by this paper
• Two Is Better Than One

  2009cited by this paper
• A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors.

  2005influential reference
• Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine.

  2005cited by this paper
• Regulation of the human WEE1Hu CDK tyrosine 15‐kinase during the cell cycle.

  1995cited by this paper

• CREB1-BCL2 drives mitochondrial resilience in RAS GAP-dependent breast cancer chemoresistance

  2025cites this paper
• Targeting DNA Damage Response and Immune Crosstalk in Cancer: Mechanistic Insights and Therapeutic Opportunities

  2025cites this paper
• WEE1 Inhibition in Cancer Therapy: Mechanisms, Synergies, Preclinical Insights, and Clinical Trials.

  2025cites this paper
• cAMP response element–binding protein: A credible cancer drug target

  2025cites this paper
• Synthetic lethal combination of CHK1 and WEE1 inhibition for treatment of castration-resistant prostate cancer

  2024cites this paper
• Stochastic variation in the FOXM1 transcription program mediates replication stress tolerance

  2024cites this paper
• Enhanced Anti-tumor Effect of Flavopiridol in Combination With Gemcitabine in Pancreatic Cancer

  2024cites this paper
• Synthetic lethal combination of CHK1 and WEE1 inhibition for treatment of castration-resistant prostate cancer

  2023cites this paper
• Adavosertib and Beyond: Biomarkers, Drug Combination and Toxicity of WEE1 Inhibitors.

  2023cites this paper
• A Phase 1 Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-Dose Gemcitabine in Metastatic Pancreatic Adenocarcinoma Patients.

  2023cites this paper
• Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.

  2022cites this paper
• Multiple-low-dose therapy: effective killing of high-grade serous ovarian cancer cells with ATR and CHK1 inhibitors

  2022cites this paper
• The expanding role of WEE1.

  2022cites this paper
• Synthetic lethality in personalized cancer therapy

  2022cites this paper
• Targeting replication stress in cancer therapy

  2022cites this paper
• RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer

  2021cites this paper
• Differential Effects of Combined ATR/WEE1 Inhibition in Cancer Cells

  2021cites this paper
• Targeting Non-Oncogene Addiction for Cancer Therapy

  2021cites this paper
• Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in Cancer

  2021cites this paper
• Store-Operated Calcium Entry: Shaping the Transcriptional and Epigenetic Landscape in Pancreatic Cancer

  2021cites this paper
• Targeting cell cycle regulation via the G2-M checkpoint for synthetic lethality in melanoma

  2021cites this paper
• It takes two to tango, and the right music: Synergistic drug combinations with cell-cycle phase-dependent sensitivities

  2021cites this paper
• A living biobank of matched pairs of patient-derived xenografts and organoids for cancer pharmacology

  2020cites this paper
• Biomarker-Guided Development of DNA Repair Inhibitors.

  2020cites this paper
• A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target

  2020cites this paper
• Pharmacological Inhibition of WEE1 Potentiates the Antitumoral Effect of the dl922-947 Oncolytic Virus in Malignant Mesothelioma Cell Lines

  2020cites this paper
• A novel siRNA–gemcitabine construct as a potential therapeutic for treatment of pancreatic cancer

  2020cites this paper
• Reply to Koh: Signaling dynamics of DNA damage response invoked by combination therapy are dose-dependent

  2019cites this paper
• Chemogenomic screening identifies the Hsp70 co-chaperone DNAJA1 as a hub for anticancer drug resistance

  2019cites this paper
• Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic Leukemia

  2019cites this paper
• Signaling dynamics of DNA damage response invoked by combination therapy are dose-dependent

  2019cites this paper
• Comparison of the different mechanisms of cytotoxicity induced by Checkpoint Kinase I inhibitors when used as single agents or in combination with DNA damage

  2019cites this paper
• Inhibition of the ATR–CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2

  2019cites this paper
• Identification of mechanisms of gemcitabine resistance using a whole genome shRNA screen in a novel in vitro coculture model of pancreatic cancer.

  2019cites this paper
• Everything in Moderation: Lessons Learned by Exploiting Moderate Replication Stress in Cancer

  2019influential citation
• The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.

  2018cites this paper
• CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications

  2018cites this paper
• Inhibition of checkpoint kinase 1 following gemcitabine-mediated S phase arrest results in CDC7- and CDK2-dependent replication catastrophe

  2018cites this paper
• Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer

  2018cites this paper
• of radioresistance in glioblastoma stem-like

  year unknowncites this paper